MedPath

To see if Levetiracetam, a new seizure control medication is better over older medication Phenobarbitone for immediate neonatal seizure control.

Phase 3
Completed
Conditions
Health Condition 1: null- neonatal seizures
Registration Number
CTRI/2015/06/005849
Lead Sponsor
Dr Nikhil D Kulkarni
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
38
Inclusion Criteria

1) > 1000 g birth weight and > 28 weeks gestation.

2)all term neonates

Exclusion Criteria

1)hypoglycemic seizures

2)neonates treated with anticonvulsants prior to admission

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recurrence of seizure and need for another anticonvulsant.Timepoint: Immediately on the day of seizure i.e. within 24 hours.
Secondary Outcome Measures
NameTimeMethod
Monitoring of adverse drug reactions of each drug like Phenobarbitone toxicity, mortality and neurodevelopmental follow up in follow up clinic.Timepoint: After treatment of seizures within 7 days and on followup at 1 month, 3 months,6 months, 9 months, 12 months, 15 months, 18 months and 24 months.
© Copyright 2025. All Rights Reserved by MedPath